SCHEDULE: Deep Track Capital Discloses 6.17% Stake in Nurix Therapeutics

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 6,345,244 shares, representing 6.17% of Nurix Therapeutics, Inc.'s common stock as of March 31, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, indicating their beneficial ownership of Nurix Therapeutics, Inc. common stock.
• The filing reports a total of 6,345,244 shares beneficially owned, which constitutes 6.17% of the outstanding common stock.
• This ownership stake was determined based on 102,843,012 shares of common stock outstanding as of January 23, 2026, as per Nurix Therapeutics' 10-K filing on January 28, 2026.
• Deep Track Capital, LP is identified as the primary entity for which David Kroin may be considered a control person.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but does not provide operational or financial performance details of the company itself.

Positives

• Significant beneficial ownership stake of 6.17% in Nurix Therapeutics, Inc. by Deep Track Capital and its affiliates.
• The filing is an amendment to a previous filing, suggesting ongoing investment activity and monitoring by Deep Track Capital.

Risks

• The filing does not explicitly detail any specific risks associated with the investment or the company itself, as it is a Schedule 13G focused on beneficial ownership.
• Potential for future changes in ownership percentage, which could impact market dynamics.

Future Outlook

The filing is a Schedule 13G, which primarily reports beneficial ownership and does not contain forward-looking statements or specific financial guidance from the company. The future outlook for Nurix Therapeutics would be found in other SEC filings by the company itself.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Deep Track Capital's substantial investment in Nurix Therapeutics, a company operating in the biotechnology sector, which is characterized by high growth potential and significant research and development activities.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest in Nurix Therapeutics, potentially influencing market perception and share price.
• Management: The significant stake held by Deep Track Capital may lead to increased engagement or dialogue between the investor and Nurix Therapeutics' management.
• Analysts: This filing provides data for analysts to incorporate into their valuation models and investment theses for Nurix Therapeutics.

Next Steps

• Deep Track Capital will continue to monitor its investment in Nurix Therapeutics.
• Further amendments to the Schedule 13G may be filed if ownership levels change significantly.

Key Dates

Recommendation

This filing is a Schedule 13G, which reports beneficial ownership and does not contain company-specific performance data or forward-looking guidance. Therefore, a 'hold' recommendation is appropriate as it reflects a neutral stance based solely on the ownership disclosure, without sufficient information to warrant a buy or sell decision.

Keywords

Nurix Therapeutics, Schedule 13G, Deep Track Capital, Beneficial Ownership, SEC Filing, Common Stock, Investment